Prevention of Bleeding

Compromised immune function associated with cancer treatment can affect morbidity and mortality. Prevention of infection in patients with cancer focuses on interventions to prevent infection because of neutropenia or other immune deficiency related to malignancy or its treatment.

PEP resources and evidence categorization is grouped for general patients with cancer and patients undergoing high-dose chemotherapy and bone marrow or any type of stem cell transplantation separately. Interventions in these two different groups of patients for the prevention of infection can be expected to differ substantially in terms of level of effectiveness.

The treatment of severe immune-related adverse events (irAE) and symptoms may require significant immunosuppression. Nurses need to be aware of the increased potential for infection, monitor patients for signs of infection, and recognize the potential for opportunistic infections. Patient education should emphasize the need to monitor for and report any signs of infection (Kyi, Hellmann, Wolchok, Chapman, & Postow, 2014).

ONS staff researchers and clinical specialists have exhaustively assessed evidenced-based research from comprehensive sources to provide you our best recommendations on Symptom Interventions for your patients.